Additionally, a novel CXCR4 inhibitor, modified with a picolinamide scaffold (CPZ1344), has entered pre-clinical research, demonstrating potential as a novel therapeutic agent against glioblastoma [28]. This evidence concerns the gene CXCR4 and glioblastoma.